Complications of tuberculosis

Purpose of review Diagnosis and management of tuberculosis (TB) remains challenging and complex because of the heterogeneity of disease presentations. Despite effective treatment, TB disease can lead to significant short-and long-term health consequences. We review potential acute and chronic complications of TB disease and current management approaches. Recent findings Acute and subacute complications of TB disease are attributable to structural damage or vascular compromise caused by Mycobacterium tuberculosis, as well as metabolic abnormalities and host inflammatory responses. TB-related sepsis is a life-threatening acute complication for which current diagnostic and management approaches are likely inadequate. Therapeutic intensification and usage of immunomodulators are areas of ongoing research. Paradoxical reaction or symptom worsening during TB treatment may benefit from corticosteroids. Despite successful cure of TB, chronic complications can arise from anatomic alterations at disease sites. Examples include mycetomas developing within residual TB cavities, impaired pulmonary function, or focal neurologic deficits from tuberculomas. Summary Effective management of TB requires attention to potential structural, metabolic, vascular, and infectious complications. In some instances, individualizing treatment regimens may be necessary. Imunosuppression and other host factors predispose to complications; others occur despite adequate treatment. Public health TB programs and health systems require additional resources to provide comprehensive TB and post-TB care.

[1]  Sandy F. Price,et al.  Trends in Tuberculosis — United States, 2013 , 2014, MMWR. Morbidity and mortality weekly report.

[2]  P. Draganov,et al.  Hepatotoxic effects of therapies for tuberculosis , 2010, Nature Reviews Gastroenterology &Hepatology.

[3]  D. Menzies,et al.  Adverse reactions to first-line antituberculosis drugs , 2006, Expert opinion on drug safety.

[4]  J. Chodakewitz,et al.  Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir , 2009, Antimicrobial Agents and Chemotherapy.

[5]  S. Lapinsky,et al.  Mycobacterium tuberculosis septic shock. , 2013, Chest.

[6]  H. Deshmukh,et al.  Massive hemoptysis due to pulmonary tuberculosis: control with bronchial artery embolization. , 1996, Radiology.

[7]  A. Denys,et al.  Successful embolization of Rasmussen's aneurysm for severe haemoptysis. , 2004, Swiss medical weekly.

[8]  A. Tunkel Dexamethasone for treatment of tuberculous meningitis in adolescents and adults , 2005, Current infectious disease reports.

[9]  H. Abeles,et al.  The destroyed tuberculous lung. , 1974, Scandinavian journal of respiratory diseases.

[10]  J. Kam,et al.  Postpneumonectomy-like syndrome presenting in a patient with treated pulmonary tuberculosis: a case report , 2013, Journal of Medical Case Reports.

[11]  Y. S. Kim,et al.  Acute respiratory distress syndrome caused by miliary tuberculosis: a multicentre survey in South Korea. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[12]  D. Schade,et al.  A practical approach to hypercalcemia. , 2003, American family physician.

[13]  Robert H. Pratt,et al.  Epidemiology of extrapulmonary tuberculosis in the United States, 1993-2006. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  S. Lawn,et al.  HIV-associated tuberculosis: relationship between disease severity and the sensitivity of new sputum-based and urine-based diagnostic assays , 2013, BMC Medicine.

[15]  R. Ruimy,et al.  Tuberculosis in the intensive care unit: a descriptive analysis in a low-burden country. , 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[16]  Jing Wang,et al.  Endobronchial tuberculosis: an overview , 2011, European Journal of Clinical Microbiology & Infectious Diseases.

[17]  G. Schecter,et al.  Linezolid in the treatment of multidrug-resistant tuberculosis. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  G. Meintjes,et al.  Management of the Immune Reconstitution Inflammatory Syndrome , 2012, Current HIV/AIDS Reports.

[19]  William R Bishai,et al.  Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial , 2009, The Lancet.

[20]  K. Dooley,et al.  Induction of Influx and Efflux Transporters and Cytochrome P450 3A4 in Primary Human Hepatocytes by Rifampin, Rifabutin, and Rifapentine , 2013, Antimicrobial Agents and Chemotherapy.

[21]  Lauren E. Manning,et al.  Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  R. Quinton,et al.  Severe hypercalcaemia following vitamin D replacement for tuberculosis-associated hypovitaminosis D. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[23]  K. Guntupalli,et al.  Predictors of development and outcome in patients with acute respiratory distress syndrome due to tuberculosis. , 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[24]  S. Vong,et al.  Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. , 2011, The New England journal of medicine.

[25]  M. Iademarco Availability of an Assay for Detecting Mycobacterium tuberculosis, Including Rifampin-Resistant Strains, and Considerations for Its Use — United States, 2013 , 2013, MMWR. Morbidity and mortality weekly report.

[26]  G. Churchyard,et al.  Chronic pulmonary function impairment caused by initial and recurrent pulmonary tuberculosis following treatment , 2000, Thorax.

[27]  U. Bauer,et al.  [Centers for Disease Control and Prevention (CDC)]. , 2000, Annales de dermatologie et de venereologie.

[28]  A. Pini,et al.  Paradoxical reaction during tuberculosis treatment in HIV-seronegative patients. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  T. Oppé,et al.  Vitamin D deficiency. , 1979, British medical journal.

[30]  Alimuddin Zumla,et al.  Lung remodeling in pulmonary tuberculosis. , 2005, The Journal of infectious diseases.

[31]  Lerato Mohapi,et al.  Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. , 2011, The New England journal of medicine.

[32]  Anneke Grobler,et al.  Integration of antiretroviral therapy with tuberculosis treatment. , 2011, The New England journal of medicine.

[33]  K. Dooley,et al.  Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. , 2009, The American journal of tropical medicine and hygiene.

[34]  S. Bae,et al.  Evidence for chronic lung impairment in patients treated for pulmonary tuberculosis. , 2011, Journal of infection and public health.

[35]  A. Diacon,et al.  Early Bactericidal Activity of High-Dose Rifampin in Patients with Pulmonary Tuberculosis Evidenced by Positive Sputum Smears , 2007, Antimicrobial Agents and Chemotherapy.

[36]  Charles M Heilig,et al.  Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. , 2009, American journal of respiratory and critical care medicine.

[37]  Simon Wandel,et al.  Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. , 2010, The Lancet. Infectious diseases.

[38]  Hojoong Kim,et al.  Surgical correction of postpneumonectomy-like syndrome in a patient with a tuberculosis-destroyed lung. , 2008, The Journal of thoracic and cardiovascular surgery.

[39]  S. Dorman,et al.  Comparative performance of urinary lipoarabinomannan assays and Xpert MTB/RIF in HIV-infected individuals , 2014, AIDS.

[40]  T. Shim,et al.  Pulmonary tuberculosis with acute respiratory failure , 2008, European Respiratory Journal.

[41]  Z. Hasan,et al.  Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT Study [Supplementary Cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis’ , 2013, BMC Infectious Diseases.

[42]  Dao-xin Wang,et al.  Predictors and outcome of patients with acute respiratory distress syndrome caused by miliary tuberculosis: a retrospective study in Chongqing, China , 2012, BMC Infectious Diseases.

[43]  G. Maartens,et al.  Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome , 2010, AIDS.

[44]  B. Mayosi,et al.  Interventions for treating tuberculous pericarditis. , 2002, The Cochrane database of systematic reviews.

[45]  E. Houpt,et al.  Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA , 2010, Emerging infectious diseases.

[46]  M. Sodemann,et al.  Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial. , 2009, American journal of respiratory and critical care medicine.

[47]  D. Follmann,et al.  Linezolid for treatment of chronic extensively drug-resistant tuberculosis. , 2012, The New England journal of medicine.

[48]  J. Baeten,et al.  Mycobacterium tuberculosis Bacteremia in a Cohort of HIV-Infected Patients Hospitalized with Severe Sepsis in Uganda–High Frequency, Low Clinical Sand Derivation of a Clinical Prediction Score , 2013, PloS one.

[49]  A. Bayer,et al.  Pulmonary aspergilloma. Diagnostic and therapeutic considerations. , 1983, Archives of internal medicine.

[50]  J. Farrar,et al.  Serial MRI to determine the effect of dexamethasone on the cerebral pathology of tuberculous meningitis: an observational study , 2007, The Lancet Neurology.

[51]  Charles L Daley,et al.  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. , 2003, American journal of respiratory and critical care medicine.

[52]  Johan Schoeman,et al.  Tuberculous meningitis: more questions, still too few answers , 2013, The Lancet Neurology.

[53]  R. Smego,et al.  A systematic review of the adjunctive use of systemic corticosteroids for pulmonary tuberculosis. , 2003, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[54]  Y. Ryu,et al.  Clinical outcomes and prognostic factors in patients with tuberculous destroyed lung. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[55]  R. Wilkinson,et al.  Characterization and management of paradoxical upgrading reactions in HIV-uninfected patients with lymph node tuberculosis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[56]  T. Shim,et al.  Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis , 2012, European Respiratory Journal.

[57]  Marcos Abdo Arbex,et al.  Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs. , 2010, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia.

[58]  K. Dooley,et al.  Tuberculosis and diabetes mellitus: convergence of two epidemics. , 2009, The Lancet. Infectious diseases.

[59]  R. Chaisson,et al.  Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. , 2004, American journal of respiratory and critical care medicine.

[60]  E. Kantharaj,et al.  Pharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of Tuberculosis , 2003, Antimicrobial Agents and Chemotherapy.

[61]  Marcos Abdo Arbex,et al.  Drogas antituberculose: interações medicamentosas, efeitos adversos e utilização em situações especiais - parte 1: fármacos de primeira linha , 2010 .

[62]  Marcos Abdo Arbex,et al.  Drogas antituberculose: interações medicamentosas, efeitos adversos e utilização em situações especiais - parte 1: fármacos de primeira linha , 2010 .

[63]  P. Willcox,et al.  Chronic obstructive airways disease following treated pulmonary tuberculosis. , 1989, Respiratory medicine.

[64]  S. Bilaçeroğlu,et al.  Prednisolone: a beneficial and safe adjunct to antituberculosis treatment? A randomized controlled trial. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[65]  H. A. Thomas,et al.  Embolization of multiple Rasmussen aneurysms as a treatment of hemoptysis. , 1994, Radiology.

[66]  R. Chaisson,et al.  Diagnostic Accuracy of a Urine Lipoarabinomannan Test for Tuberculosis in Hospitalized Patients in a High HIV Prevalence Setting , 2009, Journal of acquired immune deficiency syndromes.

[67]  Aspergilloma and residual tuberculous cavities--the results of a resurvey. , 1970, Tubercle.

[68]  R. Chaisson,et al.  Quantitative Analysis of a Urine-Based Assay for Detection of Lipoarabinomannan in Patients with Tuberculosis , 2010, Journal of Clinical Microbiology.

[69]  N. Santelmo,et al.  Surgery for the sequelae of postprimary tuberculosis. , 2012, Thoracic surgery clinics.

[70]  G. Borm,et al.  Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. , 2013, The Lancet. Infectious diseases.

[71]  Keertan Dheda,et al.  Determine TB-LAM lateral flow urine antigen assay for HIV-associated tuberculosis: recommendations on the design and reporting of clinical studies , 2013, BMC Infectious Diseases.

[72]  C. Peloquin Use of therapeutic drug monitoring in tuberculosis patients. , 2004, Chest.

[73]  Christopher Dye,et al.  The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. , 2003, Archives of internal medicine.

[74]  J. Critchley,et al.  Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis. , 2013, The Lancet. Infectious diseases.

[75]  K. Dooley,et al.  Pipeline of drugs for related diseases: tuberculosis , 2013, Current opinion in HIV and AIDS.

[76]  N. Dendukuri,et al.  Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults , 2014, The Cochrane database of systematic reviews.

[77]  S. Lawn,et al.  Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review , 2012, BMC Infectious Diseases.

[78]  D. Mitchison,et al.  A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[79]  L. Soto-Ramírez,et al.  [Treatment of tuberculosis]. , 1997, Gaceta medica de Mexico.

[80]  B. Mayosi,et al.  A modern approach to tuberculous pericarditis. , 2007, Progress in cardiovascular diseases.